TransBioLine

Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
TransBioLine logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
821283

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
13 999 998
EFPIA in kind
13 906 494
Total Cost
27 906 492

Summary

Predicting which potential medicines could be harmful to major organ systems is a major challenge during drug development. The TransBioLine project aims to develop biological markers (biomarkers) that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system. The biomarkers, which the project hopes to get through regulatory qualification, include indicators of tissue damage, biomarkers to aid patient stratification, and standardised tests for the detection of the biomarkers. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, and it will be able to provide the scientific community, industry and patients with detailed data and information across a large spectrum of advanced safety biomarkers. Ultimately, the new markers will not only improve the safety of new drugs, but will contribute to the better diagnosis and management of diseases.

Participants Show participants on map

EFPIA companies
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Assistance Publique - Hopitaux De Paris, Paris, France
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Landspitali University Hospital, Reykjavik, Iceland
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Servicio Andaluz De Salud, Sevilla, Spain
  • The University Of Liverpool, Liverpool, United Kingdom
  • The University Of Nottingham, Nottingham, United Kingdom
  • Universidad De Malaga, Malaga, Spain
  • Universidad De Salamanca, Salamanca, Spain
  • Universitat Zurich, Zürich, Switzerland
  • Universiteit Leiden, Leiden, Netherlands
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Abx Cro Advanced Pharmaceutical Services Forschungsgesellschaft Mbh, Oberwil, Switzerland
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
  • Metaheps GMBH, Munich, Germany
  • Mlm Medical Labs GMBH, Moenchengladbach, Germany
  • Signatope GMBH, Reutlingen, Germany
  • Synapse Research Management Partners SL, Barcelona, Spain
  • Tamirna GMBH, Vienna, Austria
Patient organisations
  • Fundacio Privada Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, Barcelona, Spain

CONTACT

Project coordinator
Michael Merz
UNIVERSITAT ZURICH
michael.merz[at]usz.ch